

STRENGTH Superior CONTROL



ROSLAREN-B 40

Rosuvastatin 40 mg + Bempedoic acid 180 mg Tablets



ROSLAREN-B 10/20

Rosuvastatin 10 mg / 20 mg + Bempedoic acid 180 mg Tablets

ROSLAREN-B 10/20

Rosuvastatin 10 mg / 20 mg + Bempedoic acid 180 mg Tablets

ROSLAREN-B 40

Rosuvastatin 40 mg + Bempedoic acid 180 mg Tablets

Background

The dual combination of Rosuvastatin and Bempedoic Acid offers a superior approach to lowering LDL cholesterol. This powerful combination addresses persistent cardiovascular risk in patients with elevated cholesterol levels, even when on maximally tolerated statin doses. Together, Rosuvastatin and Bempedoic Acid work in harmony to achieve robust lipid reduction. This synergy not only lowers LDL cholesterol more effectively but also helps reduce the risk of cardiovascular events associated with hyperlipidemia.

Description

Roslaren-B 10/20/40: Available as film coated tablet of Bempedoic acid 180 mg and Rosuvastatin 10, 20, 40 mg. This combination medication is used along with a proper diet and other medications to help lower "bad" cholesterol (such as LDL) in blood.

Indication

As adjunct to diet and maximally tolerated statin therapy for patients with ASCVD and/or heterozygous familial hypercholesterolemia who require additional LDL-C lowering.

Mechanism of Action

- Bempedoic acid acts by inhibiting adenosine triphosphate-citrate lyase (ACL) and consequently cholesterol biosynthesis, leading to increased expression of LDL receptors and increasing low-density lipoproteins (LDL-C) plasma clearance.
- Rosuvastatin competitively inhibits HMG-CoA reductase enzyme selectively and reversibly. This enzyme converts HMG-CoA to mevalonic acid in the cholesterol biosynthetic pathway which is the rate limiting step in cholesterol synthesis.

Dosage and Administration

Roslaren-B 10/20/40: The recommended dosage is one tablet a day orally with or without food or as directed by the doctor.

- 1. Clin Investig Arterioscler. 2021 May:33 Suppl 1:53-57.
- 2. Clin Med Insights Cardiol. 2012; 6: 17-33.
- 3. Am J Cardiol 2016;117:1928-1933
- 4. Future Pharmacol. 2023, 3(2), 392-406



Scan for more Prescribing Information



